MindBio Therapeutics (MBIO)

BRIEF

published on 05/14/2024 at 16:40, 6 months 20 days ago

MindBio Therapeutics Enters $66.5 Million Deal with Enveric Biosciences for Psilocin Prodrug Development

Microdosing MindBio Therapeutics Enveric Biosciences Psilocin Prodrug Neuropsychiatric Treatment
PRESS RELEASE

published on 05/14/2024 at 16:35, 6 months 20 days ago

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
MindBio to develop novel psilocin prodrug from Enveric Biosciences for neuropsychiatric indications, utilizing microdosing to minimize hallucinogenic effects of psychedelic compounds

MindBio Microdosing Enveric Biosciences Psilocin Prodrug Neuropsychiatric
BRIEF

published on 05/02/2024 at 10:05, 7 months 1 day ago

MindBio Therapeutics Advances Women’s Health and Depression Treatment Trials

Clinical Trials Microdosing LSD MindBio Therapeutics Women's Health Depression Treatment
PRESS RELEASE

published on 05/02/2024 at 10:00, 7 months 1 day ago

MindBio Therapeutics Scientists Present Landmark Women’s Health Trials. Company To Release Phase 2A Depression Trial Secondary Data This Month
MindBio Therapeutics Corp. showcases women's health trials and upcoming data presentation on Phase 2A trial of MB22001 for Major Depressive Disorder. Company pioneering microdosing LSD for mental health conditions

MindBio Therapeutics Corp. MB22001 Microdosing LSD Women's Health Trials Phase 2A Trial
BRIEF

published on 05/01/2024 at 11:25, 7 months 2 days ago

MindBio Therapeutics Explores Dual Listing Amid Successful Clinical Trials

Clinical Trials Microdosing LSD Phase 2b MindBio Therapeutics Depressive Disorder
PRESS RELEASE

published on 05/01/2024 at 11:20, 7 months 2 days ago

MindBio Is Exploring Dual Listing on A Senior Exchange with Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3
MindBio announces successful completion of Phase 1 and Phase 2a Clinical Trials for MB22001 in treating Major Depressive Disorder. Company plans dual listing on senior exchange

Dual Listing Clinical Trials MB22001 MindBio Therapeutics Depressive Disorder
BRIEF

published on 04/30/2024 at 12:10, 7 months 3 days ago

MindBio Therapeutics Launches Groundbreaking Clinical Trials for Women's Health

Clinical Trials MB22001 Microdosing LSD Women's Health PMS And PMDD
PRESS RELEASE

published on 04/30/2024 at 12:05, 7 months 3 days ago

MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
MindBio Therapeutics Corp. announces world first clinical trials in women's health using MB22001, a proprietary form of LSD for PMS treatment

Clinical Trials MindBio Therapeutics Corp. MB22001 Women's Health PMS Treatment
BRIEF

published on 04/23/2024 at 06:25, 7 months 10 days ago

MindBio Therapeutics Publishes Sleep Research in Translational Psychiatry

MB22001 Microdosing MindBio Therapeutics Sleep Research Depressive Disorders
PRESS RELEASE

published on 04/23/2024 at 06:20, 7 months 10 days ago

MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry
MindBio's sleep research using MB22001 published in Nature's Translational Psychiatry journal. Research indicates improved sleep quality & duration after microdosing, advancing treatment for depressive disorders globally

MindBio Therapeutics Corp. MB22001 Microdosing Sleep Research Depressive Disorders

Published on 12/03/2024 at 18:43, 17 minutes ago

CORRECTION FROM SOURCE: MacDonald Mines Announces Letter Of Intent With Canuc Resources Corporation
Published on 12/03/2024 at 18:00, 1 hour ago

RE Royalties Provides $6.3 Million Financing for a 200 Megawatt Solar Project in Alberta, Canada
Published on 12/03/2024 at 17:45, 1 hour 15 minutes ago

CannapharmaRX Updates on Alberta Facility Progress and International Export Strategy
Published on 12/03/2024 at 16:36, 2 hours 24 minutes ago

Coast2Coast First Aid and Aquatics Celebrates 10 Years Anniversary with 100 Free CPR Training for Marginalized Communities
Published on 12/03/2024 at 16:00, 3 hours ago

Ascend Aesthetic Partners Marks First Year Uniting Top Surgeons in Aesthetic Care Nationwide

View all ACCESSWIRE

Published on 12/03/2024 at 18:45, 14 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 12/03/2024 at 17:55, 1 hour 4 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/03/2024 at 17:45, 1 hour 15 minutes ago

Kudelski IoT and PUFsecurity Combine IoT Security Strengths to Meet the Challenges of Increasing Global Regulation
Published on 12/03/2024 at 16:41, 2 hours 18 minutes ago

TAKKT AG: Andreas Weishaar appointed as Chief Executive Officer of TAKKT AG
Published on 12/03/2024 at 16:09, 2 hours 50 minutes ago

DWK Deutsche Wasserkraft AG launches cash capital increase with subscription rights offer

View all EQS

Published on 12/03/2024 at 18:00, 1 hour ago

Covivio - Information on total number of voting rights and share capital
Published on 12/03/2024 at 17:48, 1 hour 12 minutes ago

Acquisition of BIO Habitat
Published on 12/03/2024 at 17:46, 1 hour 14 minutes ago

Saint-Gobain cancels 5 million shares
Published on 12/03/2024 at 17:41, 1 hour 19 minutes ago

241203 BENETEAU Housing cession closed
Published on 12/03/2024 at 15:00, 4 hours ago

MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES

View all LES ECHOS COMFI WIRE

News